Table 1 Model parameters, baseline values, ranges, and distributions for sensitivity analyses

1. Overall survival

   Pemigatinib: Weibull

Scale: 22.065

Shape: 1.536

17.486

1.184

27.843

1.993

Normal (22.065, 2.619)

Normal (1.536, 0.204)

(5, 12)

   mFOLFOX: log-normal

Intercept: 1.834

Scale: 0.873

1.642

0.742

2.023

1.027

Normal (1.834, 0.098)

Normal (0.873, 0.072)

(12, 16)

   5-FU: log-normal

Intercept: 1.764

Scale: 0.816

1.586

0.691

1.943

0.965

Normal (1.764, 0.091)

Normal (0.816, 0.07)

(12, 17)

2. Progression-free survival

   Pemigatinib:  log-normal

Intercept: 1.962

Scale: 0.971

1.76

0.82

2.164

1.15

Normal (1.962, 0.103)

Normal (0.971, 0.084)

(5, 12)

   mFOLFOX: log-normal

Intercept: 1.430

Scale: 0.754

1.265

0.643

1.595

0.885

Normal (1.43, 0.084)

Normal (0.754, 0.062)

(12, 16)

   5-FU:  log-normal

Intercept: 0.8

Scale: 1.067

0.57

0.91

1.031

1.251

Normal (0.8, 0.118)

Normal (1.067, 0.087)

(12, 17)

3. Genetic testing fee (NT$)

30,000

22,500

37,500

Uniform (22,500, 37,500)

Market price

4. Medication cost (per year, NT$)

   Pemigatinib

4,336,200

3,252,150

5,420,250

Uniform (3,252,150, 5,420,250)

(13)

   mFOLFOX

412,087

309,065

515,108

Gamma (412,087, 617,747)

(12)

   5-FU

177,759

133,320

222,199

Gamma (177,759, 282,466)

(12)

5. Nonmedication cost (per year, NT$)

   Pemigatinib

291,576

218,682

364,470

Gamma (291,576, 691,057)

(12)

   Chemotherapy

856,986

642,740

1,071,233

Gamma (856,986, 1,067,455)

(12)

6. Supportive care cost (per year, NT$)

497,710

373,283

622,138

Gamma (497,710, 576,562)

(12)

7. Utility

   Progression-free state

0.760

0.57

0.95

Beta (4.7, 1.5)

(21)

   Postprogression state

0.680

0.51

0.85

Beta (29, 13.6)

(21)

8. Disutility

   Intravenous therapy

0.025

0.0188

0.0313

(10, 20)

   Grade 3 and higher AEs

0.160

0.1200

0.2000

Beta (36, 193)

(22)

9. Discount rate (per year)

0.03

0.0000

0.0500

(28)

10. Conversion factor

0.9

Uniform (0.8, 1)